Physician profile
Christopher Conlon
NPI 1578598504
$810.72
in general payments reported to CMS, 2019-2025
13 companies · $79.34 in 2025
The $79.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $197 · 2021: $96.03 · 2025: $79.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $79.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $79.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $251.92 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $130.78 | 2019 | |
| Abbvie INC. | $79.34 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.35 | 2019-2020 | |
| Novo Nordisk INC | $57.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $55.80 | 2019-2020 | |
| Pfizer INC. | $38.04 | 2019 | |
| Amgen INC. | $35.03 | 2019 | |
| Amarin Pharma, INC. | $28.71 | 2019-2020 | |
| Astellas Pharma US INC | $24.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.91 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.28 | 2019 | |
| Lilly USA, LLC | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Conlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.